Recently Diagnosed with CIDP


CONFUSED? SCARED? CONCERNED?

Unfortunately, you are one in approximately 500,000 people who will contract CIDP this year. If you have been recently diagnosed with CIDP you probably have a lot of questions.

We’re Here. And we’ve Been Where You Are.

The majority of the Foundation’s volunteers are intimate with the range of emotions that come with a recent diagnosis of CIDP – a nerve disorder so rare that you probably have never heard of it.

Fortunately, There Is Help And There Is Hope.

While the “c” does stand for “chronic,” there are treatments today that can limit and better control the disorder. If caught early and treated appropriately, CIDP can be managed.

Within our community of CIDP survivors support is readily available for you. The kind of support that comes from experience.

You do not have to go through this alone. We’re here.

  • Centers of Excellence

  • Connect With Us

  • Topics of Interest

    rdday

    Walk & Roll for GBS-CIDP - Greater Delaware Valley

    Saturday, June 8, 2013 - Wilson Farm Park

    The Walk and Roll for GBS-CIDP is the new signature walk fundraising campaign of the GBS-CIDP Foundation International. This national Walk is designed to support the thousands of families forced to face the challenges caused by CIDP, GBS and its variants. Register or sponsor a participant today.

    CIDP: Diagnosis and Treatment

    Richard J. Barohn, MD, Professor and Chair Department of Neurology at the University of Kansas Medical Center, and a member of the GBS/CIDP Foundation International Medical Advisory Board gave a presentation to the Harris County Neurological Society in November – "CIDP: Diagnosis and Treatment". Sit back and watch the video (an hour long) and hear from one of the leading experts on CIDP in the world. Share it with your neurologist.

    cslbehring

    The PATH Study – CIDP Treatment with Subcutaneous Immunoglobulin

    CSL Behring is currently recruiting CIDP patients for a clinical trial. Click above link for full access to view article.

Subject: Question: